KZIA - kaziatherapeutics.com Long-Term Debt

Kazia Therapeutics (KZIA) focuses its business on treating rare neoplasms and glioblastomas, relying on payments from insurance companies and hospitals. Market price action on GURU.Markets, where the indicator stands at 0.00, links financial potential to the creation of a precision therapy ecosystem and the paxilisib molecule. However, a heavy bet on a single primary drug creates significant binary risks dependent on regulatory decisions.

This metric reflects the total volume of credit obligations with a maturity exceeding twelve months. By analyzing the trend of the business's long-term borrowed capital, an investor assesses the sustainability of the financial leverage. The amount is formed by daily aggregating debt instruments at session closing prices. A declining curve may indicate deleveraging or stagnant expansion. For Kazia Therapeutics (KZIA), this is critical, as regulatory barriers and trade disputes limit the scaling of the business.